Tyra Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $1.28B
- P/E (TTM)
- –
- Dividend yield
- –
About Tyra Biosciences
Pharmaceutical Preparations, SIC 2834
Tyra Biosciences, Inc. is a clinical-stage biotechnology company developing targeted small molecule therapies focused on Fibroblast Growth Factor Receptor (FGFR) biology. The company utilizes its proprietary SNÅP drug design platform, combining protein crystallography, cell-based assays, and animal models to discover therapies for oncology and rare genetically defined conditions. Its product pipeline includes oral dabogratinib, an FGFR3-selective candidate evaluated for low-grade upper tract urothelial carcinoma, intermediate-risk non-muscle invasive bladder cancer, and achondroplasia. Other pipeline candidates include TYRA-430 for FGF19-positive hepatocellular carcinoma and TYRA-200 for FGFR2-altered intrahepatic cholangiocarcinoma.
The company operates in the biotechnology sector and conducts research and development activities in the United States. Its operations span clinical evaluation of its drug candidates across multiple research sites and patient cohorts globally. Tyra Biosciences maintains its principal executive offices in Carlsbad, California.
Summary of the business section of Tyra Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Tyra Biosciences, Inc.
- Headquarters
- Carlsbad, CA
- Address
- 2656 State Street 92008
- Phone
- (619) 728-4760
- Website
- tyra.bio
- Employees
- 87, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Diego, California
Stock & identifiers
- Ticker
- TYRA
- Exchange
- Nasdaq
- IPO date
- Sep 15, 2021
- Shares outstanding
- 60M, Jul 31, 2026
- Public float
- $297.30M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1863127
- CUSIP
- 90240B106
- ISIN
- US90240B1061
- EIN
- 83-1476348
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Todd Harris | President and CEO, Director | 1,438,495 |
| Yuliya Rueb | Vice President, Finance (PAO) | 11,258 |
| Alan Fuhrman | Chief Financial Officer | 37,115 |
| Bhavesh Ashar | Chief Operating Officer | 15,013 |
| Douglas J. Warner | Chief Medical Officer | 25,000 |
| Daniel Bensen | Chief Discovery Officer | 146,981 |
| Capital Healthcare Fund LP RA | Director | 10,096,004 |
| Rajeev M. Shah | Director | 8,477,275 |
| Peter Kolchinsky | Director | 9,909,154 |
| RA Capital Nexus Fund, L.P. | Director | 4,047,120 |
| Ra Capital Management, L.P. | Director | 10,259,291 |
| Rehan Verjee | Director | 972 |
| Susan Moran | Director | 0 |
| Adele M. Gulfo | Director | 4,000 |
| Jake Simson | Director | – |
| Stephen Michael Rothenberg | Director | 0 |
| Robert J. More | Director | 3,823,425 |
| Habib J. Dable | Director | 0 |
| Gilla Kaplan | Director | 28,231 |
| Nina S. Kjellson | Director | 4,144,590 |
Employees
Headcount reported in annual reports
“As of February 25, 2026, we had 87 full-time employees, including a total of 21 employees with M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 15, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 10, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |